Scott M. Coiante - 12 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
SVP, Chief Financial Officer
Signature
/s/ Scott M. Coiante
Issuer symbol
LXRX
Transactions as of
12 Feb 2026
Net transactions value
$0
Form type
4
Filing time
17 Feb 2026, 16:06:19 UTC
Previous filing
18 Feb 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coiante Scott M SVP, Chief Financial Officer 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING /s/ Scott M. Coiante 17 Feb 2026 0001608536

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Award $0 +272,680 $0.000000 272,680 12 Feb 2026 Common Stock 272,680 Direct F1, F2
transaction LXRX Stock Option (Right to Buy) Award $0 +409,020 $0.000000 409,020 12 Feb 2026 Common Stock 409,020 $1.37 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
F3 Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.